Estrogel / Patches / Implants
Symptoms, Causes & Treatment
Hormone replacement therapy (HRT) using Estrogel, patches, and implants delivers oestrogen transdermally, safely treating menopausal symptoms while avoiding the VTE and stroke risks associated with oral oestrogen tablets.
What Are Estrogel, Patches & Implants?
Estrogel, transdermal patches, and subcutaneous implants are three of the most widely prescribed forms of hormone therapy (HT) in the UK. Each one delivers oestradiol — the most potent naturally occurring form of oestrogen — directly into the bloodstream through the skin or underlying tissue, bypassing the digestive system entirely.
This matters because oral oestrogen tablets pass through the liver on their way into the bloodstream, which can affect clotting factors and increase the risk of blood clots. With Estrogel, patches, and implants, none of that happens — the hormone goes straight to where it is needed, which is why UK clinical guidelines (NICE NG23) now favour these non-oral routes for most women starting hormone therapy.
All three options treat the same underlying issue — a drop in oestrogen that occurs during perimenopause, menopause, premature ovarian insufficiency, or surgical menopause — but they differ in how they are used, how the dose is adjusted, and how long each one lasts. Your clinician will help you find the right fit based on your symptoms, lifestyle, and medical history.
A prescription is required for all three. An online consultation with a licensed clinician is the quickest way to discuss which option is right for you and get started the same day.
Menopausal Symptoms Treated by HRT
Menopausal symptoms arise from oestrogen withdrawal. Transdermal HRT relieves these symptoms effectively while minimising systemic risks.
Hot flushes and night sweats · Vaginal dryness and discomfort · Low libido · Mood changes, anxiety, and low mood · Poor sleep · Joint aches · Brain fog and poor concentration · Irregular or absent periods · Urinary symptoms
Unexpected or heavy vaginal bleeding on HRT (requires urgent gynaecological assessment) · Severe headache, visual disturbance, or speech difficulty on HRT (possible stroke) · Unilateral leg pain and swelling (possible DVT) · Chest pain or breathlessness (possible PE)
Unexpected vaginal bleeding · DVT (leg pain and swelling) · PE (chest pain, breathlessness) · Stroke (severe headache, visual change, speech difficulty) while on HRT — seek emergency assessment.
Why Use Estrogel, Patches & Implants?
HRT replaces declining oestrogen (and progestogen where needed) in menopausal women. The route and formulation are chosen based on individual health history and preferences.
Oestrogen (as Estrogel, patches, or implants) is the cornerstone of HRT for managing menopausal symptoms. Estrogel is a transdermal gel applied daily to the skin. Patches are changed twice weekly or weekly. Implants are subcutaneous pellets inserted every 6 months.
Women with a uterus must take progestogen alongside oestrogen to protect the endometrium from hyperplasia and cancer. Sequential regimens mimic a menstrual cycle; continuous combined regimens are used after 12 months of amenorrhoea.
Transdermal oestrogen (gel, patches) does not increase VTE or stroke risk, unlike oral oestrogen. UK guidelines favour transdermal routes for women at increased cardiovascular or thrombotic risk. Mirena IUS is the preferred progestogen for uterine protection with transdermal oestrogen.
HRT reduces the risk of osteoporosis and fragility fractures, reduces cardiovascular disease when started early in menopause (within 10 years or before age 60), and reduces all-cause mortality in this window. Benefits outweigh risks for most women under 60.
Combined HRT (oestrogen + progestogen) is associated with a small increased risk of breast cancer, equivalent to drinking one glass of wine daily. Risk returns to baseline 2–5 years after stopping. Oestrogen-only HRT (hysterectomised women) does not increase breast cancer risk.
Testosterone is an important HRT component for women with low libido, low energy, and cognitive symptoms not resolved by oestrogen alone. Testogel is applied in small doses to the skin. It is safe, evidence-based, and not associated with virilisation at physiological doses.
Key Risk Factors
Assessing and Monitoring HRT
Menopause is a clinical diagnosis in women over 45. FSH testing is not routinely required. Investigations are needed for premature ovarian insufficiency, abnormal bleeding on HRT, or to assess bone density.
HRT Regimens: Gel, Patches & Implants
Transdermal oestrogen is titrated to symptom control. Progestogen is added for uterine protection. Testosterone may be added for low libido and fatigue.
Supportive Measures
Apply Estrogel to alternate arms or thighs and allow to dry. Change patches on the same days each week. Rotate sites. Report breakthrough bleeding, breast changes, or new symptoms to your GP. Use vaginal oestrogen for local symptoms at any stage of HRT.
Long-Term HRT Management
HRT is a long-term treatment with no arbitrary duration limit. Annual reviews assess symptom control, side effects, and the benefit-risk balance. Women with premature menopause need HRT until at least age 51. Specialist menopause clinic referral is available for complex or high-risk cases.
When to Seek Help
You develop sudden leg pain, swelling or redness · You experience sudden breathlessness or chest pain · You have an unexplained severe headache, sudden visual changes, or weakness on one side · You notice unexplained, heavy, or post-coital vaginal bleeding.
Your symptoms are not adequately controlled on your current regimen · You are experiencing significant side effects · You have been on hormone therapy for 12 months without a clinical review · You are considering switching between delivery methods · You are new to hormone therapy and unsure where to start.
Getting the Most from HRT Safely
Safe and effective HRT requires choosing the right formulation, progestogen, and route for each woman’s individual health profile.
Use transdermal oestrogen (gel or patches) rather than oral HRT. Transdermal oestrogen does not increase VTE or stroke risk. Oral oestrogen increases clotting factor production in the liver, raising thrombotic risk.
Women with a uterus must take progestogen alongside oestrogen. Use body-identical micronised progesterone (Utrogestan) or Mirena IUS. Progestogen protects the endometrium from oestrogen-induced hyperplasia and cancer.
Attend NHS breast cancer screening (mammography every 3 years from age 50–70). Inform your screening team that you are taking HRT. Perform monthly breast self-examination. Report any new breast lumps or nipple changes to your GP promptly.
Use vaginal oestrogen for genitourinary symptoms such as vaginal dryness, pain during sex, and recurrent UTI. Vaginal oestrogen has minimal systemic absorption and is safe long-term, including in most women with a history of breast cancer.
Review HRT at least annually with your GP. Assess symptom control, side effects, and the ongoing benefit-risk balance. HRT should be continued as long as benefits outweigh risks — there is no arbitrary age or duration limit for otherwise healthy women.
Start HRT during the ‘window of opportunity’ — within 10 years of menopause or before age 60. HRT started in this window provides the greatest cardiovascular and bone protective benefits and carries the best safety profile.
Speak to a Clinician About HRT Options
All three options require a prescription from a licensed clinician. Through The GP Service you can consult online, discuss which product suits you, and receive your prescription the same day — without a waiting room or a wait for a GP appointment.
Expert clinical advice, when you need it.
Estrogel, Patches & Implants — FAQs
HRT is the most effective treatment for menopausal symptoms, reducing hot flushes and night sweats by 80–90%. It prevents osteoporosis, reduces cardiovascular disease when started within 10 years of menopause, and may reduce all-cause mortality. Benefits outweigh risks for most healthy women under 60.
Combined HRT is associated with a small increased breast cancer risk, equivalent to drinking one unit of alcohol daily. Oestrogen-only HRT does not increase breast cancer risk. Transdermal oestrogen has a safer cardiovascular and thrombotic profile than oral oestrogen tablets.
Estrogel is a transdermal oestrogen gel applied daily to the arms, thighs, or abdomen. Unlike oral HRT, it does not increase VTE or stroke risk. Dose is titrated to symptom response. It is the preferred route in women with cardiovascular risk factors, obesity, or migraines.
Yes. Women with a uterus must take progestogen to protect the endometrium. Micronised progesterone (Utrogestan) is the preferred body-identical progestogen with a better side effect profile. Mirena IUS provides effective local progestogen protection alongside transdermal oestrogen.
There is no arbitrary age or duration limit for HRT. It should continue as long as benefits outweigh risks. Women with premature menopause should continue until at least age 51. Symptoms often return when HRT is stopped. Annual review ensures ongoing appropriateness.
Seek urgent help if you develop unexplained vaginal bleeding, unilateral leg swelling (DVT), chest pain, breathlessness (PE), or severe headache on HRT. These require same-day or emergency assessment. Do not stop HRT abruptly without medical advice.
Testosterone is increasingly prescribed for women with menopausal low libido, fatigue, and brain fog not resolved by oestrogen alone. Applied as a small amount of gel to the skin, at physiological female doses it does not cause virilisation and is evidence-based and safe.
A GP can prescribe Estrogel, patches, and Utrogestan, monitor treatment response, manage side effects, and refer to a specialist menopause clinic for complex cases. Annual HRT reviews are recommended. Online consultations are appropriate for routine HRT prescribing and review.